Latest Italy News

Ramsay Health Care is set to simplify its corporate structure by distributing its majority stake in European healthcare provider Ramsay Santé directly to shareholders, enabling focused growth strategies for both entities.

Hansen Technologies has reported a remarkable half-year performance with a 7.3% revenue increase and a staggering 31,000% rise in statutory net profit, underpinned by a strategic acquisition of the Digitalk Group.

OncoSil Medical’s CEO Nigel Lange has agreed to a 10% salary reduction, opting instead to receive shares at a significant premium, reinforcing executive commitment to shareholder value and cost discipline.

International Graphite Limited has reported pilot-scale testwork results exceeding purity targets for expandable graphite, underpinning plans for a European production facility.

Altamin Limited has obtained a retrospective Environmental Impact Assessment approval for its Gorno Project in Italy, strengthening its regulatory footing and supporting strategic options for development.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

Altamin Limited progresses its Lazio geothermal lithium and SOP project with key technical studies and grant funding, while advancing a strategic sale process for its Gorno polymetallic project. The company bolsters its balance sheet through a successful entitlement offer raising A$5.39 million.

ADX Energy reported a 24% drop in production due to mechanical issues but is advancing well workovers and new drilling, supported by a $3.5 million capital raise and plans for a dual listing in Oslo.

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.

Fluence Corporation Limited has reported a robust FY 2025 with a 52.3% revenue increase and record new orders, driven by a strategic pivot to higher-margin Smart Product Solutions and recurring revenue streams.

Fluence Corporation Limited reported a positive net operating cash flow of US$3.824 million for the December 2025 quarter, ending with a strong cash position of US$16.64 million. The company’s disciplined spending and financing activities underpin its stable liquidity outlook.